Daan Gene Statistics
Total Valuation
Daan Gene has a market cap or net worth of CNY 8.45 billion. The enterprise value is 7.95 billion.
Market Cap | 8.45B |
Enterprise Value | 7.95B |
Important Dates
The last earnings date was Wednesday, April 30, 2025.
Earnings Date | Apr 30, 2025 |
Ex-Dividend Date | Jun 14, 2024 |
Share Statistics
Daan Gene has 1.40 billion shares outstanding. The number of shares has decreased by -7.43% in one year.
Current Share Class | 1.40B |
Shares Outstanding | 1.40B |
Shares Change (YoY) | -7.43% |
Shares Change (QoQ) | -5.27% |
Owned by Insiders (%) | 1.82% |
Owned by Institutions (%) | 9.03% |
Float | 934.05M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 10.26 |
PB Ratio | 1.03 |
P/TBV Ratio | 1.14 |
P/FCF Ratio | 38.72 |
P/OCF Ratio | 23.90 |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | -15.62 |
EV / Sales | 9.65 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | 36.44 |
Financial Position
The company has a current ratio of 2.91, with a Debt / Equity ratio of 0.02.
Current Ratio | 2.91 |
Quick Ratio | 1.85 |
Debt / Equity | 0.02 |
Debt / EBITDA | n/a |
Debt / FCF | 0.60 |
Interest Coverage | -84.18 |
Financial Efficiency
Return on equity (ROE) is -6.20% and return on invested capital (ROIC) is -5.30%.
Return on Equity (ROE) | -6.20% |
Return on Assets (ROA) | -4.67% |
Return on Invested Capital (ROIC) | -5.30% |
Return on Capital Employed (ROCE) | -8.87% |
Revenue Per Employee | 476,216 |
Profits Per Employee | -294,194 |
Employee Count | 1,730 |
Asset Turnover | 0.08 |
Inventory Turnover | 2.90 |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -12.63% in the last 52 weeks. The beta is 0.83, so Daan Gene's price volatility has been lower than the market average.
Beta (5Y) | 0.83 |
52-Week Price Change | -12.63% |
50-Day Moving Average | 5.89 |
200-Day Moving Average | 5.91 |
Relative Strength Index (RSI) | 58.47 |
Average Volume (20 Days) | 16,236,168 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Daan Gene had revenue of CNY 823.85 million and -508.95 million in losses. Loss per share was -0.37.
Revenue | 823.85M |
Gross Profit | 165.21M |
Operating Income | -741.46M |
Pretax Income | -543.27M |
Net Income | -508.95M |
EBITDA | -404.07M |
EBIT | -741.46M |
Loss Per Share | -0.37 |
Balance Sheet
The company has 890.81 million in cash and 131.14 million in debt, giving a net cash position of 759.67 million or 0.54 per share.
Cash & Cash Equivalents | 890.81M |
Total Debt | 131.14M |
Net Cash | 759.67M |
Net Cash Per Share | 0.54 |
Equity (Book Value) | 8.19B |
Book Value Per Share | 5.65 |
Working Capital | 2.17B |
Cash Flow
In the last 12 months, operating cash flow was 353.44 million and capital expenditures -135.25 million, giving a free cash flow of 218.19 million.
Operating Cash Flow | 353.44M |
Capital Expenditures | -135.25M |
Free Cash Flow | 218.19M |
FCF Per Share | 0.16 |
Margins
Gross margin is 20.05%, with operating and profit margins of -90.00% and -61.78%.
Gross Margin | 20.05% |
Operating Margin | -90.00% |
Pretax Margin | -65.94% |
Profit Margin | -61.78% |
EBITDA Margin | -49.05% |
EBIT Margin | -90.00% |
FCF Margin | 26.48% |
Dividends & Yields
Daan Gene does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | -99.14% |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | 7.43% |
Shareholder Yield | n/a |
Earnings Yield | -6.02% |
FCF Yield | 2.58% |
Stock Splits
The last stock split was on May 19, 2021. It was a forward split with a ratio of 1.6.
Last Split Date | May 19, 2021 |
Split Type | Forward |
Split Ratio | 1.6 |
Scores
Daan Gene has an Altman Z-Score of 4.92.
Altman Z-Score | 4.92 |
Piotroski F-Score | n/a |